SCHEMBL6011947

SCHEMBL6011947

O=C(C1CCNCC1)N1CCC(/C=C/c2ccc(Cl)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 4/20 0.50
▸ KMT2A Q03164 2/20 0.43
▸ GPR183 P32249 2/20 0.43
▸ CNR1 P21554 1/20 0.42
▸ CHRNB2 P17787 1/20 0.42
▸ CHRNA3 P32297 1/20 0.42
▸ CHRNA4 P43681 1/20 0.42
▸ CHRNB3 Q05901 1/20 0.42
▸ CHRNA6 Q15825 1/20 0.42
▸ GAA P10253 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ FNTA P49354 1/20 0.41
▸ FNTB P49356 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ KCNH2 Q12809 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14261831 0.81 MAOB (0.45) MAOBGAANPC1RAB9AL3MBTL1
SCHEMBL19994650 0.80 MAOB (0.55) MAOBKMT2AGAANPC1RAB9A
SCHEMBL19994654 0.80 MAOB (0.55) MAOBKMT2AGAANPC1RAB9A
SCHEMBL6012082 0.80 MAOB (0.50) MAOBKMT2AGPR183GAANPC1
SCHEMBL10069269 0.79 MAOB (0.51) MAOBKCNH2NPSR1
Hydrochloric Acid SCHEMBL2720583 0.79 MAOB (0.49) MAOBKMT2AGPR183GAANPC1
Hydrochloric Acid SCHEMBL2720581 0.79 MAOB (0.49) MAOBKMT2AGPR183GAANPC1
SCHEMBL13391197 0.76 MGLL (0.65) KMT2AMEN1
SCHEMBL2723040 0.76 MAOB (0.54) MAOBKMT2AGAANPC1RAB9A
SCHEMBL2723038 0.76 MAOB (0.54) MAOBKMT2AGAANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1785415-B1 PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC (JP) 2012-05-02 — — EP disclosed
US-20080070898-A1 Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof ASTELLAS PHARMA INC. (JP) 2008-03-20 — — US disclosed
US-20080070898-A1 Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof ASTELLAS PHARMA INC. (JP) 2008-03-20 — — US disclosed
EP-1785415-A1 PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Astellas Pharma Inc. (JP) 2007-05-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070898-A1 Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof TRPV1, TRPA1, CACNA1D MAOB 3198/4885KMT2A 722/4885GPR183 2602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback